SUPERIOR GROUP OF COMPANIES INC
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
Contents
Note
NOTE*8***** –Net IncomePer Share:**
The Company’s basic net income per share is computed based on the weighted average number of shares of common stock outstanding for the period. Diluted net income per share includes the effect of the Company’s outstanding stock options, stock appreciation rights, nonvested shares of restricted stock and nonvested performance shares, if the inclusion of these items is dilutive.
The following table presents a reconciliation of basic and diluted net income per share for the periods presented:
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net income used in the computation of basic and diluted net income per share (in thousands) | $600 | $1,213 | $4,512 | $2,101 |
| Weighted average shares outstanding - basic | 16,221,073 | 15,987,007 | 16,124,553 | 15,935,001 |
| Dilutive common stock equivalents | 548,224 | 137,809 | 486,822 | 186,572 |
| Weighted average shares outstanding - diluted | 16,769,297 | 16,124,816 | 16,611,375 | 16,121,573 |
| Net income per share: | ||||
| Basic | $0.04 | $0.08 | $0.28 | $0.13 |
| Diluted | $0.04 | $0.08 | $0.27 | $0.13 |
Awards to purchase 295,361 and 1,268,882 shares of common stock with weighted average exercise prices of $21.90 and $15.19 per share were outstanding during thethree months ended* June 30, 2024* and2023, respectively, but werenot included in the computation of diluted net income per share because the awards’ exercise prices were greater than the average market price of the common shares.
Awards to purchase 347,718 and 1,138,927 shares of common stock with weighted average exercise prices of $21.38 and $16.11 per share were outstanding during thesix months ended* June 30, 2024* and2023, respectively, but werenot included in the computation of diluted net income per share because the awards’ exercise prices were greater than the average market price of the common shares.
16
N**OTE9 – Operating Segment Information:
The Company manages and reports the following segments:
Branded Products segment: Primarily through our signature marketing brands BAMKO® and HPI®, we produce and sell customized merchandising solutions, promotional products and branded uniform programs. Branded products are sold to customers in a wide range of industries, including retail chain, food service, entertainment, technology, transportation and other industries. The segment currently has sales offices in the United States, Canada, and Brazil, with support services in China and India.
Healthcare Apparel segment: Primarily through our signature marketing brands Fashion Seal Healthcare®, Wink® and CID Resources, we manufacture (throughthird parties or in our own facilities) and sell a wide range of healthcare apparel, such as scrubs, lab coats, protective apparel and patient apparel. This segment sells its products to healthcare laundries, dealers, distributors, retailers and consumers primarily in the United States.
Contact Centers: Through multiple The Office Gurus® entities, including our subsidiaries in El Salvador, Belize, Jamaica, Dominican Republic and the United States (collectively, “TOG”), we provide outsourced, nearshore business process outsourcing, contact and call-center support services to North American customers.
Intersegment eliminations include the elimination of revenues and costs from services provided by the Contact Centers segment to the Company’stwo other segments. Such costs are recognized as selling and administrative expenses in the Branded Products and Healthcare Apparel segments. Income and expenses related to corporate functions that arenot specifically attributable to an individual reportable segment are presented within Other in the tables below.
During thefourth quarter of2023, our chief operating decision maker began to evaluate the performance of our segments using Segment EBITDA instead of income before income taxes. The Company has modified its presentation of segment performance to be consistent with this change, including prior periods presented for consistent and comparable presentation. Amounts that are included in income before income tax expense and excluded from Segment EBITDA include the following: interest expense and depreciation and amortization expense.
The following tables set forth financial information related to the Company’s operating segments (in thousands):
| Branded Products · Healthcare Apparel · Contact Centers · Intersegment Eliminations · Other · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| For the Three Months Ended June 30, 2024: | ||||||||
| Net sales | $81,296 | $26,592 | $24,832 | $(984) | $ | - | $131,736 | |
| Segment EBITDA | 6,724 | 1,277 | 3,181 | - | (5,623) | $5,559 | ||
| Supplemental information: | ||||||||
| Depreciation and amortization | $1,567 | $956 | $753 | $ | - | $92 | $3,368 | |
| Capital expenditures | $322 | $554 | $413 | $ | - | $10 | $1,299 | |
| Branded Products · Healthcare Apparel · Contact Centers · Intersegment Eliminations · Other · Total | ||||||||
| For the Three Months Ended June 30, 2023: | ||||||||
| Net sales | $79,592 | $28,072 | $22,758 | $(1,260) | $ | - | $129,162 | |
| Segment EBITDA | 6,988 | 1,929 | 3,252 | - | (4,741) | 7,428 | ||
| Supplemental information: | ||||||||
| Depreciation and amortization | $1,710 | $976 | $662 | $ | - | $80 | $3,428 | |
| Capital expenditures | $736 | $64 | $683 | $ | - | $46 | $1,529 | |
17
| Branded Products · Healthcare Apparel · Contact Centers · Intersegment Eliminations · Other · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| For the Six Months Ended June 30, 2024: | ||||||||
| Net sales | $168,364 | $55,829 | $48,384 | $(1,999) | $ | - | $270,578 | |
| Segment EBITDA | 16,671 | 3,912 | 6,127 | - | (11,520) | $15,190 | ||
| Supplemental information: | ||||||||
| Depreciation and amortization | $3,067 | $1,893 | $1,476 | $ | - | $184 | $6,620 | |
| Capital expenditures | $587 | $727 | $573 | $ | - | $87 | $1,974 | |
| Branded Products · Healthcare Apparel · Contact Centers · Intersegment Eliminations · Other · Total | ||||||||
| For the Six Months Ended June 30, 2023: | ||||||||
| Net sales | $161,443 | $56,226 | $44,814 | $(2,548) | $ | - | $259,935 | |
| Segment EBITDA | 14,498 | 3,501 | 6,045 | - | (9,713) | 14,331 | ||
| Supplemental information: | ||||||||
| Depreciation and amortization | $3,374 | $1,950 | $1,330 | $ | - | $162 | $6,816 | |
| Capital expenditures | $2,007 | $526 | $1,064 | $ | - | $46 | $3,643 | |
The following table reconciles income before income tax expense to Segment EBITDA (in thousands):
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Income before income tax expense | $650 | $1,376 | $5,242 | $2,321 |
| Interest expense | 1,541 | 2,624 | 3,328 | 5,194 |
| Depreciation and amortization | 3,368 | 3,428 | 6,620 | 6,816 |
| Segment EBITDA | $5,559 | $7,428 | $15,190 | $14,331 |
18
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.